Curt Nonomaque Announces Plan to Retire and Byron Jobe is Named New President and CEO
IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. announces that Curt Nonomaque, president and CEO, plans to retire after serving in his role for nearly 15 years. He will remain in his current role with the company through March 31, 2018. Byron Jobe, Vizient’s current president, chief administrative and financial officer, has been named president and CEO of the company by the Vizient Board of Directors effective April 1, 2018. Today’s leadership announcements are the result of a multi-year succession plan that has been thoughtfully developed and executed by Vizient’s Board.
David Blom, president and chief executive officer of OhioHealth and chair of Vizient’s Board of Directors, said, “In the ever-changing health care market, providers expect more value than ever before from their strategic partners. Under Curt’s leadership, Vizient has become health care’s largest member-driven performance improvement company, serving more than 3,100 health systems and delivering more than $5 billion in member value annually. The company is in a position of strength thanks to Curt and his team, and there is no better person to lead Vizient into the future than Byron Jobe. He brings deep experience and a strong skill set to the job, having led complex financial and growth-related endeavors for the company. Byron has played an active role in shaping the company’s strategic direction and has contributed to its operational strength and financial growth.”
Throughout his career, Jobe has held leadership roles in the areas of strategy, operations and finance. Jobe began his career at the company (then named VHA Inc.) in 1994, where he focused on corporate planning and business development. Jobe left the organization in 1999 to work in the health care technology sector, returning in 2007. Jobe’s broad and diverse experience includes positions with PwC, Baylor Scott & White Health and Healthvision.
“Byron is the right person to lead Vizient into the future,” said Curt Nonomaque, “He has extensive experience across all our business lines and has a relentless focus on driving member and company value. He has a long track record of success and has led the development of multiple joint ventures, mergers and acquisitions for the company – most notably, the 2015 merger with University HealthSystem Consortium followed by the 2016 acquisition of the MedAssets’ SCM and Sg2 businesses. A consummate professional, Byron is a values-driven leader who will advocate for our employees and our members.”
Jobe said, “Today’s announcement is the highlight of my career. Since returning to VHA in 2007, I’ve had the privilege to work with Curt and his leadership team. Over the past ten years, the company has been on a growth trajectory fueled by a solid strategic plan and member-focused delivery. I look forward to the future as we continue to build industry-leading solutions for our members while positioning the company as the leader in health care performance improvement.”
Nonomaque led the successful transformation of Vizient into a stronger and more focused organization aligned to help members achieve improvements in cost, variation, quality and strategy. Working hand-in-hand with his leadership team and Board, he helped the company execute its multi-year strategic plan focused on fulfilling the company’s purpose – to ensure members deliver exceptional, cost-effective care.
During his tenure, Vizient and its enterprise of companies achieved many notable accomplishments:
- Created Novation, a joint venture with University HealthSystem Consortium, to become health care’s largest supply chain company;
- Launched Provista to serve the supply needs of non-acute members;
- Successfully managed the largest transition of group purchasing volume when Children’s Hospital Association selected Novation as its supply chain partner;
- Developed Excelerate, a joint venture with Cleveland Clinic, focused on strategic sourcing;
- Merged VHA Inc, University HealthSystem Consortium and Novation to form Vizient, Inc.;
- Acquired MedAssets’ SCM and Sg2 businesses to create health care’s largest member-driven performance improvement company.
Blom added, “Curt and his leadership team have positioned the company incredibly well for the future. Beyond the impressive bottom-line results, Curt has been particularly focused on creating a values-driven organization. He has fostered an atmosphere where collaboration, adaptability and resourcefulness are rewarded. This has resulted in a spirit of creativity, innovation and member-focused service that will continue to grow under Byron’s leadership. The plans for succession and the CEO transition process have had extensive involvement of the Board over the past several years. The Board is confident that in the years to come, Vizient employees and members will benefit from the company’s programs and services.”
Full bios, photos and other materials can be accessed here.
About Vizient, Inc.
Vizient, Inc., the largest member-driven health care performance improvement company in the country, provides innovative data-driven solutions, expertise and collaborative opportunities that lead to improved patient outcomes and lower costs. Vizient’s diverse membership base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents more than $100 billion in annual purchasing volume. The Vizient brand identity represents the integration of VHA Inc., University HealthSystem Consortium and Novation, which combined in 2015, as well as MedAssets’ Spend and Clinical Resource Management (SCM) segment, including Sg2, which was acquired in 2016. In 2017, Vizient again received a World’s Most Ethical Company designation from the Ethisphere Institute. Vizient’s headquarters are in Irving, Texas, with locations in Chicago and other cities across the United States. Please visit www.vizientinc.com as well as our newsroom, blog, Twitter, LinkedIn and YouTube pages for more information about the company.